Sellas finds public path

Sellas Life Sciences Group (Hamilton, Bermuda) will merge with Galena Biopharma Inc.(NASDAQ:GALE) to form Sellas Life Sciences Group Inc.

The combined company's pipeline will include galinpepimut-S (WT1 vaccine). Sellas said it has discussed its Phase III protocol with FDA for the compound to treat acute myelogenous leukemia (AML) and malignant pleural mesothelioma (MPM), but declined to provide a timeline for the start of Phase III trials. The compound has Orphan Drug designation in the U.S. and EU, and Fast Track designation in the U.S. for both indications...